An internal medicine physician is called to the bedside of a 24-year-old male patient who is receiving care in the critical care unit for diabetic ketoacidosis. The patient was admitted 14 hours prior and has been treated with continuous intravenous fluids, a regular insulin infusion, and an electrolyte protocol. The nursing staff reports that his vital signs are stable, and he is now awake, conversational, and asking for a meal.
Recent laboratory studies demonstrate:
| Laboratory Test | Result |
|---|---|
| Sodium | 140 mEq/L |
| Potassium | 4.4 mEq/L |
| Chloride | 108 mEq/L |
| Bicarbonate | 22 mEq/L |
| Blood glucose | 165 mg/dL |
The clinical team determines the patient is ready to transition to a subcutaneous insulin regimen. Arrange the following steps for transitioning therapies and monitoring in the most appropriate chronological sequence.
- 1Verify closure of the serum anion gap and the patient's ability to tolerate oral intake.
- 2Administer a calculated dose of subcutaneous long-acting and short-acting insulin.
- 3Maintain the continuous intravenous insulin infusion for an additional 1 to 2 hours.
- 4Discontinue the continuous intravenous regular insulin infusion.
- 5Implement point-of-care capillary blood glucose monitoring before meals and at bedtime.
Answer
The correct sequence is to first verify resolution of ketoacidosis (closed anion gap and ability to eat), then administer subcutaneous insulin, maintain the intravenous insulin drip for a 1-to-2-hour overlap period, discontinue the intravenous drip, and finally implement routine point-of-care glucose monitoring.
The safe transition from intravenous to subcutaneous insulin in a patient with diabetic ketoacidosis (DKA) requires a precise sequence to prevent rebound ketoacidosis. First, DKA resolution must be confirmed by documenting a closed anion gap (12 mEq/L or less), blood glucose < 200 mg/dL, and the patient's ability to tolerate oral intake. Once confirmed, subcutaneous insulin must be administered. Because subcutaneous insulin requires 1 to 2 hours to reach systemic therapeutic levels, the intravenous insulin infusion must be maintained during this overlap window. Discontinuing the intravenous insulin prematurely creates a gap in insulin coverage, which leads to rapid lipolysis, ketogenesis, and relapse of DKA. After the 1-to-2-hour overlap, the intravenous drip is stopped, and routine point-of-care glucose monitoring begins to evaluate the efficacy of the new subcutaneous regimen.
Step-by-Step Solution
Key Concept
Transitioning from intravenous to subcutaneous insulin in diabetic ketoacidosis requires confirming anion gap closure and maintaining a 1-to-2-hour overlap of intravenous insulin after administering the subcutaneous dose to prevent rebound acidosis.